150 related articles for article (PubMed ID: 37811998)
1. Istaroxime: A Novel Therapeutic Agent for Acute Heart Failure.
Newbury D; Frishman W
Cardiol Rev; 2023 Oct; ():. PubMed ID: 37811998
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure.
Gheorghiade M; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Valentini G; Sabbah HN;
J Am Coll Cardiol; 2008 Jun; 51(23):2276-85. PubMed ID: 18534276
[TBL] [Abstract][Full Text] [Related]
4. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure.
Sabbah HN; Imai M; Cowart D; Amato A; Carminati P; Gheorghiade M
Am J Cardiol; 2007 Jan; 99(2A):41A-46A. PubMed ID: 17239704
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the New Inotropic Agent Istaroxime in Acute Heart Failure.
Forzano I; Mone P; Mottola G; Kansakar U; Salemme L; De Luca A; Tesorio T; Varzideh F; Santulli G
J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36556120
[TBL] [Abstract][Full Text] [Related]
6. Istaroxime: A rising star in acute heart failure.
Aditya S; Rattan A
J Pharmacol Pharmacother; 2012 Oct; 3(4):353-5. PubMed ID: 23326115
[TBL] [Abstract][Full Text] [Related]
7. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial.
Shah SJ; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Grzybowski J; Valentini G; Sabbah HN; Gheorghiade M;
Am Heart J; 2009 Jun; 157(6):1035-41. PubMed ID: 19464414
[TBL] [Abstract][Full Text] [Related]
8. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?
Khan H; Metra M; Blair JE; Vogel M; Harinstein ME; Filippatos GS; Sabbah HN; Porchet H; Valentini G; Gheorghiade M
Heart Fail Rev; 2009 Dec; 14(4):277-87. PubMed ID: 19238540
[TBL] [Abstract][Full Text] [Related]
9. Current drugs and medical treatment algorithms in the management of acute decompensated heart failure.
Triposkiadis F; Parissis JT; Starling RC; Skoularigis J; Louridas G
Expert Opin Investig Drugs; 2009 Jun; 18(6):695-707. PubMed ID: 19426120
[TBL] [Abstract][Full Text] [Related]
10. Cellular Mechanisms Underlying the Low Cardiotoxicity of Istaroxime.
Racioppi MF; Burgos JI; Morell M; Gonano LA; Vila Petroff M
J Am Heart Assoc; 2021 Jul; 10(14):e018833. PubMed ID: 34219467
[TBL] [Abstract][Full Text] [Related]
11. Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition.
Ferrandi M; Barassi P; Tadini-Buoninsegni F; Bartolommei G; Molinari I; Tripodi MG; Reina C; Moncelli MR; Bianchi G; Ferrari P
Br J Pharmacol; 2013 Aug; 169(8):1849-61. PubMed ID: 23763364
[TBL] [Abstract][Full Text] [Related]
12. SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy.
Torre E; Arici M; Lodrini AM; Ferrandi M; Barassi P; Hsu SC; Chang GJ; Boz E; Sala E; Vagni S; Altomare C; Mostacciuolo G; Bussadori C; Ferrari P; Bianchi G; Rocchetti M
Cardiovasc Res; 2022 Mar; 118(4):1020-1032. PubMed ID: 33792692
[TBL] [Abstract][Full Text] [Related]
13. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure.
Micheletti R; Palazzo F; Barassi P; Giacalone G; Ferrandi M; Schiavone A; Moro B; Parodi O; Ferrari P; Bianchi G
Am J Cardiol; 2007 Jan; 99(2A):24A-32A. PubMed ID: 17239701
[TBL] [Abstract][Full Text] [Related]
14. Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function.
Arici M; Ferrandi M; Barassi P; Hsu SC; Torre E; Luraghi A; Ronchi C; Chang GJ; Peri F; Ferrari P; Bianchi G; Rocchetti M; Zaza A
J Pharmacol Exp Ther; 2023 Jan; 384(1):231-244. PubMed ID: 36153005
[TBL] [Abstract][Full Text] [Related]
15. Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium.
Wallner M; Khafaga M; Kolesnik E; Vafiadis A; Schwantzer G; Eaton DM; Curcic P; Köstenberger M; Knez I; Rainer PP; Pichler M; Pieske B; Lewinski DV
Oncotarget; 2017 Jul; 8(30):49264-49274. PubMed ID: 28514771
[TBL] [Abstract][Full Text] [Related]
16. Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output.
Gheorghiade M; Ambrosy AP; Ferrandi M; Ferrari P
Discov Med; 2011 Aug; 12(63):141-51. PubMed ID: 21878191
[TBL] [Abstract][Full Text] [Related]
17. Modulation of sarcoplasmic reticulum function by PST2744 [istaroxime; (E,Z)-3-((2-aminoethoxy)imino) androstane-6,17-dione hydrochloride)] in a pressure-overload heart failure model.
Rocchetti M; Alemanni M; Mostacciuolo G; Barassi P; Altomare C; Chisci R; Micheletti R; Ferrari P; Zaza A
J Pharmacol Exp Ther; 2008 Sep; 326(3):957-65. PubMed ID: 18539651
[TBL] [Abstract][Full Text] [Related]
18. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function.
Ghali JK; Smith WB; Torre-Amione G; Haynos W; Rayburn BK; Amato A; Zhang D; Cowart D; Valentini G; Carminati P; Gheorghiade M
Am J Cardiol; 2007 Jan; 99(2A):47A-56A. PubMed ID: 17239705
[TBL] [Abstract][Full Text] [Related]
19. Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial.
Carubelli V; Zhang Y; Metra M; Lombardi C; Felker GM; Filippatos G; O'Connor CM; Teerlink JR; Simmons P; Segal R; Malfatto G; La Rovere MT; Li D; Han X; Yuan Z; Yao Y; Li B; Lau LF; Bianchi G; Zhang J;
Eur J Heart Fail; 2020 Sep; 22(9):1684-1693. PubMed ID: 31975496
[TBL] [Abstract][Full Text] [Related]
20. Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart Failure.
Luraghi A; Ferrandi M; Barassi P; Arici M; Hsu SC; Torre E; Ronchi C; Romerio A; Chang GJ; Ferrari P; Bianchi G; Zaza A; Rocchetti M; Peri F
J Med Chem; 2022 May; 65(10):7324-7333. PubMed ID: 35580334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
